US Biosimilar Industry Projected to Surge With CAGR of 40% Through 2028: New Study Highlights Market Growth and Trends –

US Biosimilar Industry Projected to Surge With CAGR of 40% Through 2028: New Study Highlights Market Growth and Trends –

US Biosimilar Industry Projected to Surge With CAGR of 40% Through 2028: New Study Highlights Market Growth and Trends –

DUBLIN–(BUSINESS WIRE)–The “US Biosimilar industry outlook to 2028” report has been added to’s offering.

The comprehensive analysis offers an in-depth look at the surge in demand for cost-effective therapeutic alternatives, with biosimilar drugs spearheading a transformative movement within the healthcare sector.

The study delves into the complex ecosystem of the US Biosimilar market, identifying the critical factors that contribute to its projected Compound Annual Growth Rate (CAGR) of approximately 40% over the next five years.

Notably, the report examines the industry’s response to the needs of a growing geriatric population and an escalating incidence of chronic diseases. Moreover, it highlights the impact of strategic partnerships that are reshaping the competitive landscape.

Key Insights from the Report:

  • The cost-effectiveness of Biosimilar drugs is key to market growth as patients seek affordable alternatives to high-priced generic drugs.
  • An aging population and the rise in chronic disease cases are significant drivers for the industry.
  • Strategic partnerships among leading pharmaceutical companies are fostering innovation and accelerating market expansion.

The Competitive Edge in Biosimilars:

The US Biosimilar market is characterized by a robust presence of both domestic and global pharmaceutical titans. The research highlights the strategies employed by these entities to navigate the market dynamics and enhance their foothold within the industry.

Recent developments such as the FDA approval of novel biosimilar drugs indicate a promising future, with industry players making significant strides in various therapeutic areas including oncology and chronic disease management.

Monoclonal Antibodies Spearhead Market Domination:

The report stresses that Monoclonal Antibodies continue as frontrunners within the drug class segment, attributing their dominance to high efficacy rates in treating serious conditions like cancer. It underscores their critical role in harnessing the body’s immune responses to combat diseases.

A Closer Look at the Oncology Segment:

With the oncology application leading the charge, the study assesses the escalating cancer rates and the resultant demand for effective treatments. Biosimilar drugs, known for their success in cancer therapy, are spotlighted as vital to the industry’s progression.

Geographic Highlights: The northern region of the US stands out as a major contributor to the market’s growth, home to a confluence of leading healthcare establishments and pharmaceutical innovators.

With an extensive examination of market segments, competitor strategies, and geographic hotspots, the research broadens understanding of the current state and future trajectory of the US Biosimilar industry.

The US Biosimilar industry continues to signal a robust and optimistic outlook, as this research publication signifies a valuable asset for those invested in the future of health and medicine.

Company Coverage:

  • Pfizer
  • Amgen
  • Biogen
  • Viatris
  • Coherus Biosciences

Key Topics Covered:

1. Executive Summary

2. US Biosimilar Market Overview

2.1 Taxonomy of the Market

2.2 Industry Value Chain

2.3 Ecosystem

2.4 Government Regulations/Initiatives for the Market

2.5 Growth Drivers of the US Biosimilar Market

2.6 Issues and Challenges of the US Biosimilar Market

2.7 Impact of COVID-19 on US Biosimilar Market

2.8 SWOT Analysis

3.US Biosimilar Market Size, 2017 – 2022

4. US Biosimilar Market Segmentation

4.1 By Drug Class, 2017 – 2022

4.2 By Application 2017 – 2022

4.3 By Regional Split (North/East/West/South/Central), 2017 – 2022

5. Competitive Landscape

5.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements

5.2 Strategies Adopted by Leading Players

5.3 Company Profiles

5.3.1 Pfizer

5.3.2 Biogen

5.3.3 Coherus Biosciences

5.3.4 Viatris

5.3.5 Amgen

6. US Biosimilar Market, 2022-2028

7. US Biosimilar Market, Market Segmentation

7.1 By Drug class, 2022 – 2028

7.2 By Application, 2022 – 2028

7.3 By Regional Split (North/East/West/South/Central), 2022 – 2028

8. Analyst Recommendations

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900